Compare Merck & Co., Inc. (MRK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Simon Property Group Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Merck & Co., Inc. is far larger — about 5.4× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Simon Property Group Inc for 99 Days on average.
| MRK | SPG | |
|---|---|---|
Market Cap | $351.28B | $64.59B |
Volume | 7,969,665 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $156.43 | $236.70 |
52-Week Low | $82.49 | $173.35 |
Typical Hold Time | 98 Days | 99 Days |
Enterprise Value | $398.04B | $93.03B |
Dividend Yield | 2.39% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Simon Property Group (SPG) trades at $199.61, up 1.02% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results, including revenue of $6.36B and net income of $4.63B, with a net margin of 72.7%. Recent news highlights leasing demand strength and a new media network launch, while analysts maintain a consensus price target of $222.90.
SPG offers value with a P/E of 14.09 and robust profitability, but faces risks from high debt levels and interest rate sensitivity. The stock's upside potential hinges on sustained retail demand and effective debt management, with institutional sentiment leaning neutral amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
